Syndax Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Syndax Pharmaceuticals

08/05/2023 23:08

* Syndax Pharmaceuticals Inc  SNDX.OQ  reported a quarterly
adjusted loss of 59 cents​​ per share for the quarter ended in
March. The mean expectation of seven analysts for the quarter
was for a loss of 60 cents per share.
    * Reported revenue was zero​; analysts expected $428.57
thousand. 
    * Syndax Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 59 cents​.
    * The mean earnings estimate of analysts had risen by
about 8.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Syndax Pharmaceuticals Inc shares had fallen by 5.0% this
quarter and lost 21.2% so far this year.
    * The company reported a quarterly loss of $41.13 million.
    * Wall Street's median 12-month price target for Syndax
Pharmaceuticals Inc is $33.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
8 at 10:08 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.60          -0.59          Beat
 Dec. 31 2022      -0.65          -0.62          Beat
 Sep. 30 2022      -0.63          -0.58          Beat
 Jun. 30 2022      -0.64          -0.62          Beat